Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Improving Drug Delivery using Red Blood Cell Hitchhiking

Description:

 

Problem

 

A major challenge in drug delivery is ensuring that the drug reaches the target organ at a concentration sufficient to treat the disease. This is particularly problematic for acute illnesses of the vasculature, such as acute respiratory distress syndrome (ARDS), ischemic stroke, and myocardial infarction. In these diseases, patients are often too sick to tolerate off-target drug side effects, and systemically delivered drugs rarely accumulate to a significant extent in the organs affected by pathology.

 

Solution

 

Drs. Jacob Brenner and Vladimir Muzykantov have developed a drug delivery system that can address these challenges. The drug delivery system, “Red Blood Cell (RBC)-Hitchhiking Nanoparticles” (RHNs), utilizes soft nanoparticles, such as liposomes and nanogels, loaded with drugs and the natural properties of RBCs to target the lung endothelium. The nanoparticles are adsorbed onto the surface of the RBC and delivered intravascularly. Once the nanoparticle-RBCs encounter their first capillary bed, the RBCs are physically squeezed, causing the release of the drug-loaded nanoparticles into the capillary endothelium. Since delivery is dependent on the squeezing of RBCs, the nanoparticles do not release their drug cargo until they enter the pulmonary capillaries. This approach minimizes delivery of the drug to sites other than the target organ and ensures that sufficient drug concentration reaches the target site.

 

Image courtesy of Brenner JS et al. Nat Commun, 9(1):2684 covered by Creative Commons license.

 

  * TECHNOLOGY UPDATE *

 

Drs. Brenner and Muzykantov have developed a dual targeted RBC hitchhiking platform nanotchenology for precise, tunable delivery of targeted therapeutics

 

Applications

 

- Targeted drug delivery for treatment of diseases of the capillary endothelium: ARDS, ischemic stroke, acute myocardial infarction

 

Advantages

 

- Minimize off-target drug effects

- Maximize delivery of drug to target organ

- Can be delivered intravenously to target the lungs or via intra-arterial catheters to deliver to any target organ, including the brain and heart

 

Stage Of Development

 

- Validation studies completed in rodent and pig models

 

Intellectual Property

 

- US utility patent pending 15/722,583

 

Reference Media

 

- Brenner JS et al. Nat Commun, 9(1):2684

- Pan DC et al. Sci Rep, 8(1):1615

- Muzykantov VR and Brenner JS. Hepatology, 68(5): 1672

 

Desired Partnerships

 

- License

- Co-development

 

Docket : 16-7880

Download pdf


Patent Information:
For Information, Contact:
Jessica Casciano
Licensing Officer, PSOM Licensing Group
University of Pennsylvania
(215) 573-5414
casciano@upenn.edu
Inventors:
Jacob Brenner
Vladimir Muzykantov
Keywords: